Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2017

01-12-2017 | Original Article

The Role and Regulation of the 11 Beta-Hydroxysteroid Dehydrogenase Enzyme System in Patients with Inflammatory Bowel Disease

Authors: M. Hussey, G. Holleran, S. Smith, Mark Sherlock, D. McNamara

Published in: Digestive Diseases and Sciences | Issue 12/2017

Login to get access

Abstract

Introduction

Glucocorticoids are known to modulate a number of immunological responses including counteracting inflammation. Within tissues expressing the glucocorticoid and mineralocorticoid receptors including the colon, glucocorticoid metabolism is regulated by the isoenzymes of 11ß-hydroxysteroid dehydrogenase (11β-HSD). 11β-HSD1 acts as an oxidoreductase converting inactive cortisone into active cortisol, while 11β-HSD2 acts as a dehydrogenase converting active cortisol to inactive cortisone. Hexose-6 phosphate dehydrogenase (H6PDH) is a key regulator of 11β-HSD1 activity via its generation of NADPH. Variations in the 11β-HSD enzyme system in relation to levels of expression and regulation may have a role in IBD. The aim of this study was to investigate possible abnormalities of 11β-HSD enzyme system in the colon of patients with IBD.

Methods

By using quantitative real-time PCR, we investigated the transcription levels of 11β-HSD1 and 2 in colonic tissue from IBD patients and healthy controls undergoing a colonoscopy for disease assessment. Disease activity was recorded using clinical (Mayo Score/Harvey–Bradshaw Index), Biochemical (C-reactive protein), histological, and endoscopic parameters. In addition, transcription levels of H6PDH and the glucocorticoid receptor alpha (GR-α) as well as key pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, Rela (subunit for NF Kappa B)) were later examined among this group, and results were correlated with 11β-HSD2 gene expression. Results and patient demographics were expressed as a mean (and SD), and differences between IBD patients and control groups were analyzed using a Student’s t test or Mann–Whitney U test as appropriate, with a p value of ≤0.05 considered significant. Results were controlled for disease activity as outlined above.

Results

Results have demonstrated a significant downregulation in 11β-HSD2 expression in IBD patients compared with controls (13.8 ± 17.1 au vs. 318.4 ± 521.1 au, p = 0.01), whereas levels of 11β-HSD1 did not appear to vary across the two groups. Among IBD patients, there was a trend toward higher 11β-HSD1 expression in inflamed tissue compared with matched non-inflamed tissue (422.1 ± 944 au vs. 102.2 ± 103.9, P = 0.09). Levels of H6PDH and the GR-α expression did not appear to vary among active inflamed IBD tissue and controls. As a result, we examined the association between pro-inflammatory cytokines and levels of 11β-HSD2 expression. Results showed an upregulation of key pro-inflammatory cytokine mRNA expression (TNF-α, IL-1β, IL-6) during inflammation with an associated downregulation of 11β-HSD2 mRNA expression when compared to controls. Dysregulation in this pathway could have a potential role in IBD pathogenesis and may account for exogenous glucocorticoid resistance in IBD. Further work assessing the role of the 11β-HSD enzyme system in steroid-resistant subjects is warranted.
Literature
1.
go back to reference Zbankova S, Bryndova J, Leden P, Kment M, Svec A, Pacha J. 11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis. J Gastroenterol Hepatol. 2007;22:1019–1023.CrossRefPubMed Zbankova S, Bryndova J, Leden P, Kment M, Svec A, Pacha J. 11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis. J Gastroenterol Hepatol. 2007;22:1019–1023.CrossRefPubMed
2.
go back to reference Arlt W, Stewart PM. Adrenal corticosteroid biosynthesis, metabolism, and action. Endocrinol Metab Clin North Am. 2005;34:293–313.CrossRefPubMed Arlt W, Stewart PM. Adrenal corticosteroid biosynthesis, metabolism, and action. Endocrinol Metab Clin North Am. 2005;34:293–313.CrossRefPubMed
3.
go back to reference Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev. 1996;17:587–609.CrossRefPubMed Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev. 1996;17:587–609.CrossRefPubMed
4.
go back to reference Creed TJ, Probert CS. Review article: steroid resistance in inflammatory bowel disease—mechanisms and therapeutic strategies. Aliment Pharmacol Ther. 2007;25:111–122.CrossRefPubMed Creed TJ, Probert CS. Review article: steroid resistance in inflammatory bowel disease—mechanisms and therapeutic strategies. Aliment Pharmacol Ther. 2007;25:111–122.CrossRefPubMed
5.
go back to reference Smith R, Maguire JA, Stein-Oakley AN, et al. Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues. J Clin Endocrinol Metab. 1996;81:3244–3248.PubMed Smith R, Maguire JA, Stein-Oakley AN, et al. Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues. J Clin Endocrinol Metab. 1996;81:3244–3248.PubMed
6.
go back to reference Whorwood CB, Ricketts ML, Stewart PM. Epithelial cell localization of type 2 11 beta hydroxysteroid dehydrogenase in rat and human colon. Endocrinology. 1994;135:2533–2541.CrossRefPubMed Whorwood CB, Ricketts ML, Stewart PM. Epithelial cell localization of type 2 11 beta hydroxysteroid dehydrogenase in rat and human colon. Endocrinology. 1994;135:2533–2541.CrossRefPubMed
7.
go back to reference Bryndova J, Zbankova S, Kment M, Pacha J. Colitis up-regulates local glucocorticoid activation and down-regulates inactivation in colonic tissue. Scand J Gastroenterol. 2004;39:549–553.CrossRefPubMed Bryndova J, Zbankova S, Kment M, Pacha J. Colitis up-regulates local glucocorticoid activation and down-regulates inactivation in colonic tissue. Scand J Gastroenterol. 2004;39:549–553.CrossRefPubMed
8.
go back to reference Lavery GG, Walker EA, Tiganescu A, et al. Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab. 2008;93:3827–3832.CrossRefPubMedPubMedCentral Lavery GG, Walker EA, Tiganescu A, et al. Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab. 2008;93:3827–3832.CrossRefPubMedPubMedCentral
9.
go back to reference White PC, Mune T, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev. 1997;18:135–156.PubMed White PC, Mune T, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev. 1997;18:135–156.PubMed
10.
12.
go back to reference Terao M, Itoi S, Matsumura S, et al. Local glucocorticoid activation by 11β-hydroxysteroid dehydrogenase 1 in keratinocytes. Am J Pathol. 2016;186:1499–1510.CrossRefPubMed Terao M, Itoi S, Matsumura S, et al. Local glucocorticoid activation by 11β-hydroxysteroid dehydrogenase 1 in keratinocytes. Am J Pathol. 2016;186:1499–1510.CrossRefPubMed
13.
go back to reference Ergang P, Vytáčková K, Svec J, Bryndová J, Mikšík I, Pácha J. Upregulation of 11β-hydroxysteroid dehydrogenase 1 in lymphoid organs during inflammation in the rat. J Steroid Biochem Mol Biol. 2011;126:19–25.CrossRefPubMed Ergang P, Vytáčková K, Svec J, Bryndová J, Mikšík I, Pácha J. Upregulation of 11β-hydroxysteroid dehydrogenase 1 in lymphoid organs during inflammation in the rat. J Steroid Biochem Mol Biol. 2011;126:19–25.CrossRefPubMed
15.
go back to reference McKay L, Cidlowski JA. Molecular control of immune/inflammatory responses; intereactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Edocr Rev. 1999;20:435–459. McKay L, Cidlowski JA. Molecular control of immune/inflammatory responses; intereactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Edocr Rev. 1999;20:435–459.
16.
go back to reference Cooper MS, Bujalska I, Rabbitt E, et al. Modulation of 11 beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res. 2001;16:1037–1044.CrossRefPubMed Cooper MS, Bujalska I, Rabbitt E, et al. Modulation of 11 beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res. 2001;16:1037–1044.CrossRefPubMed
17.
go back to reference Takahashi KI, Fukushima K, Sasano H, et al. Type II 11beta-hydroxysteroid dehydrogenase expression in human colonic epithelial cells of inflammatory bowel disease. Dig Dis Sci. 1999;44:2516–2522.CrossRefPubMed Takahashi KI, Fukushima K, Sasano H, et al. Type II 11beta-hydroxysteroid dehydrogenase expression in human colonic epithelial cells of inflammatory bowel disease. Dig Dis Sci. 1999;44:2516–2522.CrossRefPubMed
18.
go back to reference Stegk JP, Ebert B, Martin HJ, Maser E. Expression profiles of human 11beta-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases. Mol Cell Endocrinol. 2009;301:104–108.CrossRefPubMed Stegk JP, Ebert B, Martin HJ, Maser E. Expression profiles of human 11beta-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases. Mol Cell Endocrinol. 2009;301:104–108.CrossRefPubMed
Metadata
Title
The Role and Regulation of the 11 Beta-Hydroxysteroid Dehydrogenase Enzyme System in Patients with Inflammatory Bowel Disease
Authors
M. Hussey
G. Holleran
S. Smith
Mark Sherlock
D. McNamara
Publication date
01-12-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4753-1

Other articles of this Issue 12/2017

Digestive Diseases and Sciences 12/2017 Go to the issue

UNM Clinical Case Conferences

A Fairy Tale with a Hairy Tail

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.